Syngene International Limited

BSE: 539268 NSE: SYNGENE
Syngene International Limited - pharma in Bangalore, Karnataka, India. FY 2026 financials and compliance.
CIN L85110KA1993PLC014937 Incorporated 18 November 1993 ROC Bangalore HQ Bangalore, Karnataka, India
Active Listed - NSE: SYNGENE · BSE: 539268 Public Limited Company pharma
Data last updated
Revenue · FY 2026
₹3,738.7 Cr
▲ 2.64% YoY
Computed EBITDA · FY 2026
₹989.2 Cr
▼ 11.17% YoY
Net profit · FY 2026
₹316.7 Cr
▼ 36.17% YoY
Authorised capital
₹500 Cr
Registered with MCA
Paid-up capital
₹403.67 Cr
Issued & subscribed
Open charges
₹375 Cr
Satisfied ₹1,783.71 Cr
Company age
33 yrs
Est. 1993
Employees · EPFO
5,599
Latest available

About Syngene International Limited

Data last updated: 14 July 2026

Syngene International Limited is a public limited company based in Bangalore, Karnataka, India, a subsidiary of Biocon Limited. It specialises in pharma contract r and d, a part of the broader pharmaceuticals sector. Incorporated on 18 November 1993, the company has been in operation for over 33 years.

Registered with ROC Bangalore under CIN L85110KA1993PLC014937. Listed on BSE: 539268 and NSE: SYNGENE.

Capital: an authorised share capital of ₹500 Cr and a paid-up capital of ₹403.67 Cr. Formerly known as Syngene International Private Limited. It is led by directors including Catherine Patricia Rosenberg and Sharmila Abhay Karve.

Last AGM: 23 July 2025. Financial statements filed for year ended 31 March 2025. Office: Biocon Sez Biocon Park, Bangalore, Karnataka.

As per NSE-filed consolidated financials for FY 2026, the company reported a revenue of ₹3,738.7 Cr, a growth of 2.64% compared to the previous year. The net worth stands at ₹4,839.1 Cr (up 2.38% YoY). Total assets are valued at ₹7,054.7 Cr (up 3.81% YoY).

The company has a workforce of approximately 5,599 employees as per the latest available data. It operates as a subsidiary of Biocon Limited. Its group structure includes 2 subsidiaries.

The company is associated with 1 brand - Syngene. As per MCA filings, the company has open charges of ₹375 Cr and satisfied charges of ₹1,783.71 Cr on record.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website syngeneintl.com.

Company Details of Syngene International Limited
CIN L85110KA1993PLC014937
Registration Number 014937
Incorporation Date 18 November 1993
ROC Bangalore
Listing Status Listed (BSE: 539268, NSE: SYNGENE)
Company Status Active
Date of Last AGM 23 July 2025
Date of Balance Sheet 31 March 2025
Parent Company Biocon Limited
Compliance Status Active Compliant
Key People
Catherine Patricia Rosenberg Director Sharmila Abhay Karve Director Kush M Parmar Director
Contact Details
  • Email
    Locked
  • Telephone
    Locked
  • Website
    syngeneintl.com
  • Social Media
  • Registered Address
    Biocon Sez Biocon Park Plot.No.2 & 3 Bommasandra Indst. Area Iv Phase Jigani Link Rd Bo, Mmasandra, Bangalore, Karnataka, India – 560099
  • Industry
    Pharma, Pharma Contract R&D
Company report
Syngene International Limited - full intelligence report
  • Historical Financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Litigation, compliance and MCA filings
  • PDF report delivered after checkout
₹799 ₹999 20% off
Secure checkout · GST invoice included

Unlock the full Syngene International Limited report

Financials, compliance, directors, charges, ownership and filings for Syngene International Limited in one report.

10-year financials Directors & ownership Charges & compliance

CIN History of Syngene International Limited

Syngene International Limited has one previous CIN (Corporate Identification Number): U51909KA1993PLC014937. The current CIN is L85110KA1993PLC014937, which is the unique identifier assigned by the Registrar of Companies.

CIN Status
L85110KA1993PLC014937 Current
U51909KA1993PLC014937 Previous

Associated Brands with Syngene International Limited

Syngene International Limited operates one associated brand: Syngene. These brands represent Syngene International Limited's diversified market presence and brand portfolio.

Brand Description Website
Syngene
Provider of contract research and manufacturing services for both small molecules and biologics syngeneintl.com

Competitors & Alternatives of Syngene International Limited

Brands and companies operating in the same space as Syngene International Limited include Abzena, Grand River Aseptic Manufacturing, Patheon and 5 more.

Competitor Description Location Founded
Abzena Abzena Provider of antibody discovery, cell line development, and bio analytics services Cambridge, United Kingdom, United Kingdom 2001
Grand River Aseptic Manufacturing Grand River Aseptic Manufacturing Sterile parenteral CDMO services for development and manufacturing are offered. Grand Rapids, United States, United States 2010
Patheon Patheon Commercial manufacturing and pharmaceutical development services for biopharmaceutical industry Durham, United States, United States 1974
Panacea Biotec Panacea Biotec Developer of biosimilars, vaccines and natural products Ambala, India, India 1984
Piramal Group Piramal Group Multinational conglomerate with diverse interests in Pharma, Financial Services and Real Estate Mumbai, India, India 1984
Maravai Life Sciences Maravai Life Sciences Provides enabling tools and services in the life sciences research and bio-production industries San Diego, United States, United States 2014
LakePharma LakePharma Provider of drug discovery on molecular biology, viral vectors and cell & protein engineering Belmont, United States, United States 2009
Insud Pharma Insud Pharma Finished formulations, APIs, and monoclonal antibodies are developed and manufactured. Madrid, Spain, Spain 1977

Business Activity of Syngene International Limited

Syngene International Limited is engaged in the principal business activity of professional, scientific and technical, with detailed activities including scientific research and development.

Main Activity Group Code Description of Main Activity Business Activity Code Description of Business Activity Turnover Percentage
M Professional, Scientific and Technical M5 Scientific research and development Locked
Premium access

Business activity turnover details for Syngene International Limited

Turnover contribution percentages and historical activity changes require an active report plan.

  • Turnover contribution
  • Historical classifications
  • Filing-level activity changes

Verified entity values are shown only after access is granted.

Auditor Details of Syngene International Limited

Syngene International Limited is audited by BSR & Co. LLP (ICAI peer reviewed, certificate valid till 2028-07-31) for the financial year 2026, as reported in its NSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.

Name Financial year Audit opinion
BSR & Co. LLP (ICAI peer reviewed, certificate valid till 2028-07-31) FY 2026 Declaration of unmodified opinion

Board of Directors of Syngene International Limited

Syngene International Limited is currently managed by 10 directors, with 21 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.

Current Directors
Name Designation Appointment Date Tenure Status
Catherine Patricia Rosenberg
Also directs: Syngene International Limited
Director 08 Aug 2000 25 Years 11 Months Current
Sharmila Abhay Karve
Also directs: Syngene International Limited, Thomas Cook (India) Limited, Csb Bank Limited and 5 more
Director 01 Aug 2019 6 Years 11 Months Current
Kush M Parmar
Also directs: Syngene International Limited
Director 22 Jun 2021 5 Years 0 Months Current
Vinita Bali
Also directs: Bajaj Auto Limited., Syngene International Limited, Cognizant Foundation
Director 31 Jul 2017 8 Years 11 Months Current
Kiran Mazumdar Shaw
Also directs: Syngene International Limited, Glenloch Properties Llp, Biocon Limited and 5 more
Director 18 Nov 1993 32 Years 8 Months Current
Sanjaya Singh
Also directs: Syngene International Limited
Director 01 Jul 2025 1 Years 0 Months Current
Showing 6 of 10 current directors. View all directors

Financials of Syngene International Limited FY 2026 filings available

Syngene International Limited reported revenue of ₹3,738.7 Cr (up 2.64% YoY) for FY 2026.

Revenue · FY 2026
₹3,738.7 Cr ▲ 2.64%
Profit · FY 2026
₹316.7 Cr ▼ 36.17%
Computed EBITDA · FY 2026
₹989.2 Cr ▼ 11.17%
Revenue₹ Cr · Consolidated02,0004,000FY 2020: ₹2,012 Cr2,012FY 2020FY 2021: ₹2,184 Cr · +8.6% YoY2,184+8.6%FY 2021FY 2022: ₹2,604 Cr · +19.2% YoY2,604+19.2%FY 2022FY 2023: ₹3,193 Cr · +22.6% YoY3,193+22.6%FY 2023FY 2024: ₹3,489 Cr · +9.3% YoY3,489+9.3%FY 2024FY 2025: ₹3,642 Cr · +4.4% YoY3,642+4.4%FY 2025FY 2026: ₹3,739 Cr · +2.6% YoY3,739+2.6%FY 2026
Net Profit₹ Cr · Consolidated0200400600FY 2020: ₹412 Cr412FY 2020FY 2021: ₹405 Cr · -1.7% YoY405-1.7%FY 2021FY 2022: ₹396 Cr · -2.2% YoY396-2.2%FY 2022FY 2023: ₹464 Cr · +17.3% YoY464+17.3%FY 2023FY 2024: ₹510 Cr · +9.8% YoY510+9.8%FY 2024FY 2025: ₹496 Cr · -2.7% YoY496-2.7%FY 2025FY 2026: ₹317 Cr · -36.2% YoY317-36.2%FY 2026
Quarterly Revenue₹ Cr · vs same quarter last year05001,0001,500Q1'25: ₹790 Cr · -2.3% YoY790-2.3%Q1'25Q2'25: ₹891 Cr · -2.1% YoY891-2.1%Q2'25Q3'25: ₹944 Cr · +10.6% YoY944+10.6%Q3'25Q4'25: ₹1,018 Cr · +11% YoY1,018+11%Q4'25Q1'26: ₹875 Cr · +10.7% YoY875+10.7%Q1'26Q2'26: ₹911 Cr · +2.2% YoY911+2.2%Q2'26Q3'26: ₹917 Cr · -2.8% YoY917-2.8%Q3'26Q4'26: ₹1,037 Cr · +1.8% YoY1,036+1.8%Q4'26
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue from Operations ₹3,738.7 Cr ₹3,642.4 Cr ₹3,488.6 Cr ₹3,192.9 Cr ₹2,604.2 Cr ₹2,184.3 Cr ₹2,011.9 Cr
Other Income ₹70.7 Cr ₹71.8 Cr ₹90.6 Cr ₹70.9 Cr ₹52.8 Cr ₹64.6 Cr ₹81.6 Cr
Total Income ₹3,809.4 Cr ₹3,714.2 Cr ₹3,579.2 Cr ₹3,263.8 Cr ₹2,657 Cr ₹2,248.9 Cr ₹2,093.5 Cr
Cost of Materials Consumed ₹911.2 Cr ₹925.4 Cr ₹873.6 Cr ₹902.2 Cr ₹770.6 Cr ₹551.7 Cr ₹518.6 Cr
Purchases of Stock-in-Trade ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Changes in Inventories ₹7.4 Cr ₹17.1 Cr ₹56.6 Cr -₹42 Cr -₹21.6 Cr -₹25.2 Cr ₹80 Lakh
Employee Benefit Expense ₹1,104.9 Cr ₹983.9 Cr ₹888.7 Cr ₹841.7 Cr ₹718.1 Cr ₹660.2 Cr ₹580.4 Cr
Finance Costs ₹48.8 Cr ₹53.1 Cr ₹47.2 Cr ₹45.2 Cr ₹24.1 Cr ₹27.7 Cr ₹34.6 Cr
Depreciation & Amortisation ₹452.9 Cr ₹432.6 Cr ₹425.9 Cr ₹366.5 Cr ₹309.7 Cr ₹274.5 Cr ₹219.3 Cr
Other Expenses ₹796.7 Cr ₹674.2 Cr ₹655.3 Cr ₹556.6 Cr ₹341 Cr ₹325.8 Cr ₹294.2 Cr
Total Expenses ₹3,321.9 Cr ₹3,086.3 Cr ₹2,947.3 Cr ₹2,670.2 Cr ₹2,141.9 Cr ₹1,814.7 Cr ₹1,647.9 Cr
Profit Before Exceptional Items & Tax ₹487.5 Cr ₹627.9 Cr ₹631.9 Cr ₹593.6 Cr ₹515.1 Cr ₹434.2 Cr ₹445.6 Cr
Exceptional Items -₹76.6 Cr ₹32 Cr -₹11.1 Cr ₹0 -₹30.7 Cr ₹35 Cr ₹71.3 Cr
Profit Before Tax ₹410.9 Cr ₹659.9 Cr ₹620.8 Cr ₹593.6 Cr ₹484.4 Cr ₹469.2 Cr ₹516.9 Cr
Total Tax Expense ₹94.2 Cr ₹163.7 Cr ₹110.8 Cr ₹129.2 Cr ₹88.6 Cr ₹64.3 Cr ₹104.8 Cr
Net Profit ₹316.7 Cr ₹496.2 Cr ₹510 Cr ₹464.4 Cr ₹395.8 Cr ₹404.9 Cr ₹412.1 Cr
  attributable to Owners ₹0 ₹0 - ₹0 ₹0 - ₹0
  attributable to NCI ₹0 ₹0 - ₹0 ₹0 - ₹0
Other Comprehensive Income -₹196 Cr -₹14.7 Cr ₹142.6 Cr -₹97.2 Cr ₹43.3 Cr ₹190.6 Cr -₹191.6 Cr
Total Comprehensive Income ₹120.7 Cr ₹481.5 Cr ₹652.6 Cr ₹367.2 Cr ₹439.1 Cr ₹595.5 Cr ₹220.5 Cr
EBITDA (computed) ₹989.2 Cr ₹1,113.6 Cr ₹1,105 Cr ₹1,005.3 Cr ₹848.9 Cr ₹736.4 Cr ₹699.5 Cr
Basic EPS ₹7.87 ₹12.35 ₹12.71 ₹11.59 ₹9.94 ₹10.18 ₹10.38
Diluted EPS ₹7.87 ₹12.34 ₹12.69 ₹11.51 ₹9.82 ₹10.11 ₹10.35
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Total Assets ₹7,054.7 Cr ₹6,795.9 Cr ₹6,151.6 Cr ₹5,831 Cr
Non-current Assets ₹4,911.9 Cr ₹4,508.6 Cr ₹4,192.6 Cr ₹3,405.7 Cr
Current Assets ₹2,142.8 Cr ₹2,287.3 Cr ₹1,959 Cr ₹2,425.3 Cr
Property, Plant & Equipment ₹2,545.4 Cr ₹2,322.6 Cr ₹2,378.3 Cr ₹2,383.4 Cr
Inventories ₹141.3 Cr ₹155.5 Cr ₹238.5 Cr ₹332.8 Cr
Trade Receivables ₹508.8 Cr ₹526.7 Cr ₹441.6 Cr ₹529.3 Cr
Cash & Equivalents ₹228.6 Cr ₹367.1 Cr ₹85.7 Cr ₹89.5 Cr
Equity (Net Worth) ₹4,839.1 Cr ₹4,726.8 Cr ₹4,257.7 Cr ₹3,618 Cr
Equity Share Capital ₹402.9 Cr ₹402.5 Cr ₹402 Cr ₹401.4 Cr
Borrowings (Non-current) ₹0 ₹0 ₹100 Cr ₹489 Cr
Borrowings (Current) ₹9.4 Cr ₹119.6 Cr ₹41.7 Cr ₹86.3 Cr
Total Debt (computed) ₹9.4 Cr ₹119.6 Cr ₹141.7 Cr ₹575.3 Cr
Current Liabilities ₹1,552.3 Cr ₹1,396.4 Cr ₹1,144.3 Cr ₹1,188.2 Cr
Total Liabilities ₹2,215.6 Cr ₹2,069.1 Cr ₹1,893.9 Cr ₹2,213 Cr
The balance sheet became part of the exchange results-filing format in FY2023 - earlier years were not filed and are hidden.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Operating Cash Flow ₹915.2 Cr ₹1,167.6 Cr ₹1,042.1 Cr ₹823.5 Cr ₹580.6 Cr
Investing Cash Flow -₹860.4 Cr -₹744.7 Cr -₹495.6 Cr -₹656.4 Cr -₹611.5 Cr
Financing Cash Flow -₹215 Cr -₹141.8 Cr -₹551.4 Cr -₹342.5 Cr -₹31.3 Cr
Capital Expenditure ₹344 Cr ₹760.3 Cr ₹492 Cr ₹506.6 Cr ₹475.3 Cr
Free Cash Flow (computed) ₹571.2 Cr ₹407.3 Cr ₹550.1 Cr ₹316.9 Cr ₹105.3 Cr
Dividends Paid ₹50.4 Cr ₹50.3 Cr ₹50.3 Cr ₹40.1 Cr ₹0
Net Change in Cash -₹138.5 Cr ₹281.4 Cr -₹3.8 Cr -₹172.3 Cr -₹61.5 Cr
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25 Q4 FY24 Q3 FY24 Q2 FY24 Q1 FY24
Revenue from Operations ₹1,036.5 Cr ₹917.1 Cr ₹910.6 Cr ₹874.5 Cr ₹1,018 Cr ₹943.7 Cr ₹891 Cr ₹789.7 Cr ₹916.9 Cr ₹853.5 Cr ₹910.1 Cr ₹808.1 Cr
Other Income ₹22.2 Cr ₹15.4 Cr ₹15.4 Cr ₹17.7 Cr ₹18.9 Cr ₹18.3 Cr ₹16.5 Cr ₹18.1 Cr ₹16.1 Cr ₹29.3 Cr ₹21.6 Cr ₹23.6 Cr
Total Income ₹1,058.7 Cr ₹932.5 Cr ₹926 Cr ₹892.2 Cr ₹1,036.9 Cr ₹962 Cr ₹907.5 Cr ₹807.8 Cr ₹933 Cr ₹882.8 Cr ₹931.7 Cr ₹831.7 Cr
Cost of Materials Consumed ₹223.3 Cr ₹220.9 Cr ₹227.5 Cr ₹239.5 Cr ₹228.1 Cr ₹241.9 Cr ₹230.8 Cr ₹168 Cr ₹172.1 Cr ₹240.3 Cr ₹241.8 Cr ₹219.4 Cr
Purchases of Stock-in-Trade ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Changes in Inventories ₹9.8 Cr ₹8.5 Cr ₹11 Cr -₹21.9 Cr ₹6.9 Cr -₹4.5 Cr ₹5.8 Cr ₹65.5 Cr ₹30.7 Cr -₹2.9 Cr ₹25.4 Cr ₹3.4 Cr
Employee Benefit Expense ₹300.8 Cr ₹267.4 Cr ₹275 Cr ₹261.7 Cr ₹253 Cr ₹249.5 Cr ₹251.5 Cr ₹229.9 Cr ₹226.9 Cr ₹220.9 Cr ₹225.5 Cr ₹215.4 Cr
Finance Costs ₹12.1 Cr ₹11.9 Cr ₹13.2 Cr ₹11.6 Cr ₹15.9 Cr ₹12.4 Cr ₹13.1 Cr ₹11.7 Cr ₹12.9 Cr ₹10.8 Cr ₹13 Cr ₹10.5 Cr
Depreciation & Amortisation ₹111.5 Cr ₹113.7 Cr ₹116.5 Cr ₹111.2 Cr ₹106.1 Cr ₹108.7 Cr ₹110.9 Cr ₹106.9 Cr ₹111.1 Cr ₹108.1 Cr ₹104.6 Cr ₹102.1 Cr
Other Expenses ₹199.2 Cr ₹211.1 Cr ₹197.6 Cr ₹188.8 Cr ₹186.4 Cr ₹173.2 Cr ₹158.1 Cr ₹156.5 Cr ₹170.3 Cr ₹163.7 Cr ₹163.3 Cr ₹158 Cr
Total Expenses ₹856.7 Cr ₹833.5 Cr ₹840.8 Cr ₹790.9 Cr ₹796.4 Cr ₹781.2 Cr ₹770.2 Cr ₹738.5 Cr ₹724 Cr ₹740.9 Cr ₹773.6 Cr ₹708.8 Cr
Profit Before Exceptional Items & Tax ₹202 Cr ₹99 Cr ₹85.2 Cr ₹101.3 Cr ₹240.5 Cr ₹180.8 Cr ₹137.3 Cr ₹69.3 Cr ₹209 Cr ₹141.9 Cr ₹158.1 Cr ₹122.9 Cr
Exceptional Items -₹6 Cr -₹70.6 Cr ₹0 ₹0 ₹0 ₹0 ₹0 ₹32 Cr ₹0 -₹3.7 Cr -₹7.4 Cr ₹0
Profit Before Tax ₹196 Cr ₹28.4 Cr ₹85.2 Cr ₹101.3 Cr ₹240.5 Cr ₹180.8 Cr ₹137.3 Cr ₹101.3 Cr ₹209 Cr ₹138.2 Cr ₹150.7 Cr ₹122.9 Cr
Total Tax Expense ₹48.1 Cr ₹13.4 Cr ₹18.1 Cr ₹14.6 Cr ₹57.2 Cr ₹49.7 Cr ₹31.2 Cr ₹25.6 Cr ₹20.4 Cr ₹26.7 Cr ₹34.2 Cr ₹29.5 Cr
Net Profit ₹147.9 Cr ₹15 Cr ₹67.1 Cr ₹86.7 Cr ₹183.3 Cr ₹131.1 Cr ₹106.1 Cr ₹75.7 Cr ₹188.6 Cr ₹111.5 Cr ₹116.5 Cr ₹93.4 Cr
  attributable to Owners ₹0 - ₹0 ₹0 ₹0 ₹0 - - - - - -
  attributable to NCI ₹0 - ₹0 ₹0 ₹0 ₹0 - - - - - -
Other Comprehensive Income -₹85.7 Cr ₹7.1 Cr -₹138.8 Cr ₹21.4 Cr ₹55.4 Cr -₹56.9 Cr -₹40.3 Cr ₹27.1 Cr ₹40.9 Cr ₹20.6 Cr -₹28 Cr ₹109.1 Cr
Total Comprehensive Income ₹62.2 Cr ₹22.1 Cr -₹71.7 Cr ₹108.1 Cr ₹238.7 Cr ₹74.2 Cr ₹65.8 Cr ₹102.8 Cr ₹229.5 Cr ₹132.1 Cr ₹88.5 Cr ₹202.5 Cr
EBITDA (computed) ₹325.6 Cr ₹224.6 Cr ₹214.9 Cr ₹224.1 Cr ₹362.5 Cr ₹301.9 Cr ₹261.3 Cr ₹187.9 Cr ₹333 Cr ₹260.8 Cr ₹275.7 Cr ₹235.5 Cr
Basic EPS ₹3.68 ₹0.37 ₹1.67 ₹2.16 ₹4.56 ₹3.27 ₹2.64 ₹1.89 ₹4.70 ₹2.78 ₹2.90 ₹2.33
Diluted EPS ₹3.67 ₹0.37 ₹1.67 ₹2.15 ₹4.56 ₹3.26 ₹2.64 ₹1.88 ₹4.69 ₹2.77 ₹2.90 ₹2.32
Latest 12 quarters shown of 24 on record.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue from Operations ₹3,423.8 Cr ₹3,373.3 Cr ₹3,203.1 Cr ₹3,193.5 Cr ₹2,601.4 Cr ₹2,179.4 Cr ₹2,011.9 Cr
Other Income ₹66.9 Cr ₹70.5 Cr ₹88 Cr ₹70.9 Cr ₹52.8 Cr ₹64.6 Cr ₹81.6 Cr
Total Income ₹3,490.7 Cr ₹3,443.8 Cr ₹3,291.1 Cr ₹3,264.4 Cr ₹2,654.2 Cr ₹2,244 Cr ₹2,093.5 Cr
Cost of Materials Consumed ₹824.3 Cr ₹868.3 Cr ₹839.1 Cr ₹902.2 Cr ₹770.6 Cr ₹551.7 Cr ₹518.6 Cr
Purchases of Stock-in-Trade ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Changes in Inventories ₹7.4 Cr ₹17.1 Cr ₹56.6 Cr -₹42 Cr -₹21.6 Cr -₹25.2 Cr ₹80 Lakh
Employee Benefit Expense ₹904.5 Cr ₹841.7 Cr ₹761.2 Cr ₹812.2 Cr ₹697.8 Cr ₹641.5 Cr ₹572.2 Cr
Finance Costs ₹26 Cr ₹31.2 Cr ₹29.5 Cr ₹45.2 Cr ₹24.1 Cr ₹27.7 Cr ₹34.6 Cr
Depreciation & Amortisation ₹387.1 Cr ₹367.3 Cr ₹368.9 Cr ₹359.1 Cr ₹309.7 Cr ₹274.5 Cr ₹219.3 Cr
Other Expenses ₹873 Cr ₹728.6 Cr ₹667.4 Cr ₹586.8 Cr ₹361.2 Cr ₹341.4 Cr ₹303.6 Cr
Total Expenses ₹3,022.3 Cr ₹2,854.2 Cr ₹2,722.7 Cr ₹2,663.5 Cr ₹2,141.8 Cr ₹1,811.6 Cr ₹1,649.1 Cr
Profit Before Exceptional Items & Tax ₹468.4 Cr ₹589.6 Cr ₹568.4 Cr ₹600.9 Cr ₹512.4 Cr ₹432.4 Cr ₹444.4 Cr
Exceptional Items -₹73.2 Cr ₹32 Cr -₹11.1 Cr ₹0 -₹30.7 Cr ₹35 Cr ₹71.3 Cr
Profit Before Tax ₹395.2 Cr ₹621.6 Cr ₹557.3 Cr ₹600.9 Cr ₹481.7 Cr ₹467.4 Cr ₹515.7 Cr
Total Tax Expense ₹90.3 Cr ₹153.6 Cr ₹90.8 Cr ₹127.9 Cr ₹87.9 Cr ₹63.7 Cr ₹104.2 Cr
Net Profit ₹304.9 Cr ₹468 Cr ₹466.5 Cr ₹473 Cr ₹393.8 Cr ₹403.7 Cr ₹411.5 Cr
Other Comprehensive Income -₹231.5 Cr -₹8.1 Cr ₹143.1 Cr -₹97.2 Cr ₹43.3 Cr ₹190.6 Cr -₹191.6 Cr
Total Comprehensive Income ₹73.4 Cr ₹459.9 Cr ₹609.6 Cr ₹375.8 Cr ₹437.1 Cr ₹594.3 Cr ₹219.9 Cr
EBITDA (computed) ₹881.5 Cr ₹988.1 Cr ₹966.8 Cr ₹1,005.2 Cr ₹846.2 Cr ₹734.6 Cr ₹698.3 Cr
Basic EPS ₹7.58 ₹11.64 ₹11.62 ₹11.81 ₹9.89 ₹10.15 ₹10.36
Diluted EPS ₹7.57 ₹11.63 ₹11.61 ₹11.72 ₹9.77 ₹10.08 ₹10.33
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Total Assets ₹6,562.8 Cr ₹6,406.9 Cr ₹5,833.9 Cr ₹5,848 Cr
Non-current Assets ₹4,686.6 Cr ₹4,373 Cr ₹3,982 Cr ₹2,963.7 Cr
Current Assets ₹1,876.2 Cr ₹2,033.9 Cr ₹1,851.9 Cr ₹2,355.3 Cr
Property, Plant & Equipment ₹2,244 Cr ₹1,994.1 Cr ₹2,065.6 Cr ₹2,140.3 Cr
Inventories ₹136.9 Cr ₹150.3 Cr ₹234 Cr ₹332.8 Cr
Trade Receivables ₹432.5 Cr ₹469.4 Cr ₹427.5 Cr ₹484.4 Cr
Cash & Equivalents ₹120.5 Cr ₹233.5 Cr ₹66.6 Cr ₹72.1 Cr
Equity (Net Worth) ₹4,703.8 Cr ₹4,638.9 Cr ₹4,191.5 Cr ₹3,618.9 Cr
Equity Share Capital ₹402.9 Cr ₹402.5 Cr ₹402 Cr ₹401.4 Cr
Borrowings (Non-current) ₹0 ₹0 ₹100 Cr ₹489 Cr
Borrowings (Current) ₹0 ₹102.5 Cr ₹41.7 Cr ₹86.3 Cr
Total Debt (computed) ₹0 ₹102.5 Cr ₹141.7 Cr ₹575.3 Cr
Current Liabilities ₹1,418.9 Cr ₹1,328.6 Cr ₹1,098.6 Cr ₹1,157.3 Cr
Total Liabilities ₹1,859 Cr ₹1,768 Cr ₹1,642.4 Cr ₹2,229.1 Cr
The balance sheet became part of the exchange results-filing format in FY2023 - earlier years were not filed and are hidden.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Operating Cash Flow ₹831 Cr ₹1,113.8 Cr ₹913.4 Cr ₹838.4 Cr ₹582.2 Cr
Investing Cash Flow -₹783.8 Cr -₹810.4 Cr -₹383.5 Cr -₹688.2 Cr -₹611.5 Cr
Financing Cash Flow -₹177.8 Cr -₹136.5 Cr -₹536.3 Cr -₹340.2 Cr -₹31.3 Cr
Capital Expenditure ₹263.8 Cr ₹369.3 Cr ₹351.1 Cr ₹521.4 Cr ₹475.3 Cr
Free Cash Flow (computed) ₹567.2 Cr ₹744.5 Cr ₹562.3 Cr ₹317 Cr ₹106.9 Cr
Dividends Paid ₹50.4 Cr ₹50.3 Cr ₹50.3 Cr ₹40.1 Cr ₹0
Net Change in Cash -₹113 Cr ₹166.9 Cr -₹5.5 Cr -₹186.9 Cr -₹59.9 Cr
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25 Q4 FY24 Q3 FY24 Q2 FY24 Q1 FY24
Revenue from Operations ₹960 Cr ₹834.4 Cr ₹830.1 Cr ₹799.3 Cr ₹948.4 Cr ₹877.1 Cr ₹821.3 Cr ₹726.5 Cr ₹864.7 Cr ₹791.9 Cr ₹830.7 Cr ₹715.8 Cr
Other Income ₹21.6 Cr ₹14.5 Cr ₹14.2 Cr ₹16.6 Cr ₹18.4 Cr ₹18 Cr ₹16.4 Cr ₹17.7 Cr ₹15.3 Cr ₹28.8 Cr ₹21 Cr ₹22.9 Cr
Total Income ₹981.6 Cr ₹848.9 Cr ₹844.3 Cr ₹815.9 Cr ₹966.8 Cr ₹895.1 Cr ₹837.7 Cr ₹744.2 Cr ₹880 Cr ₹820.7 Cr ₹851.7 Cr ₹738.7 Cr
Cost of Materials Consumed ₹202.2 Cr ₹197.9 Cr ₹201.2 Cr ₹223 Cr ₹212.8 Cr ₹229.1 Cr ₹216.2 Cr ₹210.2 Cr ₹162.4 Cr ₹227.6 Cr ₹235.3 Cr ₹213.8 Cr
Purchases of Stock-in-Trade ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Changes in Inventories ₹9.8 Cr ₹8.5 Cr ₹11 Cr -₹21.9 Cr ₹7 Cr -₹4.6 Cr ₹5.8 Cr ₹8.9 Cr ₹30.7 Cr -₹2.8 Cr ₹25.4 Cr ₹3.3 Cr
Employee Benefit Expense ₹248.5 Cr ₹217.5 Cr ₹225.9 Cr ₹212.6 Cr ₹209.4 Cr ₹212.6 Cr ₹224.1 Cr ₹195.6 Cr ₹195.1 Cr ₹196.5 Cr ₹190.6 Cr ₹179 Cr
Finance Costs ₹6.5 Cr ₹6.2 Cr ₹7.4 Cr ₹5.9 Cr ₹10.1 Cr ₹6.7 Cr ₹7 Cr ₹7.4 Cr ₹8.5 Cr ₹6.3 Cr ₹8.6 Cr ₹6.1 Cr
Depreciation & Amortisation ₹95.3 Cr ₹97.1 Cr ₹100.1 Cr ₹94.6 Cr ₹89.6 Cr ₹92.3 Cr ₹93.7 Cr ₹91.7 Cr ₹95.7 Cr ₹93.6 Cr ₹90.9 Cr ₹88.7 Cr
Other Expenses ₹215.2 Cr ₹225.8 Cr ₹214.5 Cr ₹217.5 Cr ₹209.2 Cr ₹189.2 Cr ₹166.6 Cr ₹163.6 Cr ₹177.2 Cr ₹171.1 Cr ₹162.8 Cr ₹156.3 Cr
Total Expenses ₹777.5 Cr ₹753 Cr ₹760.1 Cr ₹731.7 Cr ₹738.1 Cr ₹725.3 Cr ₹713.4 Cr ₹677.4 Cr ₹669.6 Cr ₹692.3 Cr ₹713.6 Cr ₹647.2 Cr
Profit Before Exceptional Items & Tax ₹204.1 Cr ₹95.9 Cr ₹84.2 Cr ₹84.2 Cr ₹228.7 Cr ₹169.8 Cr ₹124.3 Cr ₹66.8 Cr ₹210.4 Cr ₹128.4 Cr ₹138.1 Cr ₹91.5 Cr
Exceptional Items -₹7.4 Cr -₹65.8 Cr ₹0 ₹0 ₹0 ₹0 ₹0 ₹32 Cr ₹0 -₹3.7 Cr -₹7.4 Cr ₹0
Profit Before Tax ₹196.7 Cr ₹30.1 Cr ₹84.2 Cr ₹84.2 Cr ₹228.7 Cr ₹169.8 Cr ₹124.3 Cr ₹98.8 Cr ₹210.4 Cr ₹124.7 Cr ₹130.7 Cr ₹91.5 Cr
Total Tax Expense ₹48.5 Cr ₹13.6 Cr ₹18 Cr ₹10.2 Cr ₹54.3 Cr ₹46.7 Cr ₹27.7 Cr ₹24.9 Cr ₹20.6 Cr ₹24.9 Cr ₹29.1 Cr ₹16.2 Cr
Net Profit ₹148.2 Cr ₹16.5 Cr ₹66.2 Cr ₹74 Cr ₹174.4 Cr ₹123.1 Cr ₹96.6 Cr ₹73.9 Cr ₹189.8 Cr ₹99.8 Cr ₹101.6 Cr ₹75.3 Cr
Other Comprehensive Income -₹102.4 Cr ₹1.5 Cr -₹150 Cr ₹19.4 Cr ₹59.7 Cr -₹55 Cr -₹39.5 Cr ₹26.7 Cr ₹41.2 Cr ₹20.6 Cr -₹27.8 Cr ₹109.1 Cr
Total Comprehensive Income ₹45.8 Cr ₹18 Cr -₹83.8 Cr ₹93.4 Cr ₹234.1 Cr ₹68.1 Cr ₹57.1 Cr ₹100.6 Cr ₹231 Cr ₹120.4 Cr ₹73.8 Cr ₹184.4 Cr
EBITDA (computed) ₹305.9 Cr ₹199.2 Cr ₹191.7 Cr ₹184.7 Cr ₹328.4 Cr ₹268.8 Cr ₹225 Cr ₹165.9 Cr ₹314.6 Cr ₹228.3 Cr ₹237.6 Cr ₹186.3 Cr
Basic EPS ₹3.68 ₹0.41 ₹1.65 ₹1.84 ₹4.34 ₹3.07 ₹2.41 ₹1.84 ₹4.73 ₹2.49 ₹2.53 ₹1.88
Diluted EPS ₹3.68 ₹0.41 ₹1.65 ₹1.83 ₹4.33 ₹3.06 ₹2.41 ₹1.84 ₹4.72 ₹2.48 ₹2.53 ₹1.87
Latest 12 quarters shown of 24 on record.
Want more history and ratios?
You're viewing the latest exchange-filed financials for Syngene International Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Shareholding Pattern of Syngene International Limited

As per the shareholding pattern filed with NSE for the quarter ended Mar 2026, promoters hold 52.68%, foreign institutional investors hold 13.90%, domestic institutional investors hold 26.44%, retail and other public shareholders hold 6.69% of Syngene International Limited. The company had 135,605 shareholders on record.

Promoters: 52.68%DII (Domestic Institutional): 26.44%FII (Foreign Institutional): 13.90%Retail & Others: 6.69%
Mar 2026
QUARTER
52.68% Promoters
26.44% DII (Domestic Institutional)
13.90% FII (Foreign Institutional)
6.69% Retail & Others
Promoter holding - history
Now 52.68% · Mar 2026High 74.55% · Dec 2015Low 52.68% · Jun 2025
51%57.3%63.5%69.8%76%Dec 2015Jun 2018Dec 2020Jun 2023Dec 2025Dec 2015: 74.55%Mar 2016: 74.55%Jun 2016: 74.55%Sep 2016: 74.52%Dec 2016: 74.52%Mar 2017: 74.51%Jun 2017: 74.51%Sep 2017: 74.50%Dec 2017: 74.46%Mar 2018: 74.45%Jun 2018: 71.65%Sep 2018: 71.11%Dec 2018: 71.06%Mar 2019: 71.05%Jun 2019: 71.04%Sep 2019: 70.77%Dec 2019: 70.70%Mar 2020: 70.69%Jun 2020: 70.65%Sep 2020: 70.61%Dec 2020: 70.59%Mar 2021: 70.58%Jun 2021: 70.43%Sep 2021: 70.42%Dec 2021: 70.41%Mar 2022: 70.41%Jun 2022: 70.29%Sep 2022: 64.86%Dec 2022: 64.86%Mar 2023: 54.88%Jun 2023: 54.80%Sep 2023: 54.79%Dec 2023: 54.79%Mar 2024: 54.79%Jun 2024: 54.72%Sep 2024: 54.72%Dec 2024: 52.74%Mar 2025: 52.74%Jun 2025: 52.68%Sep 2025: 52.68%Dec 2025: 52.68%Mar 2026: 52.68%74.55%52.68%52.68%
Shareholding trend - last 6 quarters
Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Promoters52.68%52.68%52.68%52.68%52.74%52.74%
Public47.03%47.02%47.01%47.00%46.97%46.97%
Employee Trusts0.29%0.29%0.30%0.31%0.29%0.29%
Shareholding history - year on year (as at 31 March)
Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017Mar 2016
Promoters52.68%52.74%54.79%54.88%70.41%70.58%70.69%71.05%74.45%74.51%74.55%
Public47.03%46.97%44.90%44.66%28.91%28.71%28.44%27.93%24.02%23.23%22.49%
Employee Trusts0.29%0.29%0.31%0.46%0.68%0.71%0.87%1.02%1.53%2.26%2.96%
Promoter change (YoY, %pts)-0.06-2.05-0.09-15.53-0.17-0.11-0.36-3.40-0.06-0.04-

Board & Governance of Syngene International Limited

As per the corporate governance filing with NSE for the quarter ended 31-MAR-2026, the board of Syngene International Limited has 10 directors - 6 independent and 1 executive. The board is chaired by KIRAN MAZUMDAR SHAW.

DirectorPositionOn board sinceListed boards
KIRAN MAZUMDAR SHAW Non-Executive - Non Independent Director · Chairperson 2020-04-01 4
CATHERINE PATRICIA ROSENBERG Non-Executive - Non Independent Director 2000-08-08 1
PETER JAMES JONATHAN BAINS Executive Director · CEO-MD 2025-04-01 1
VINITA BALI Non-Executive - Non Independent Director 2025-07-22 2
SHARMILA ABHAY KARVE Non-Executive - Independent Director 2019-08-01 5
KUSH PARMAR Non-Executive - Independent Director 2021-06-22 1
NILANJAN ROY Non-Executive - Independent Director 2024-04-01 1
MANJA BOERMAN Non-Executive - Independent Director 2024-06-04 1
SANJAYA SINGH Non-Executive - Independent Director 2025-07-01 1
SURESH NARAYANAN Non-Executive - Independent Director 2025-08-01 1
Board Committees
CommitteeMembers
Audit Committee SHARMILA ABHAY KARVE (Chairperson), SURESH NARAYANAN, NILANJAN ROY, VINITA BALI
Nomination and remuneration committee SURESH NARAYANAN (Chairperson), SHARMILA ABHAY KARVE, CATHERINE PATRICIA ROSENBERG, VINITA BALI, MANJA BOERMAN, SANJAYA SINGH
Stakeholders Relationship Committee NILANJAN ROY (Chairperson), CATHERINE PATRICIA ROSENBERG, MANJA BOERMAN, SURESH NARAYANAN
Risk Management Committee NILANJAN ROY (Chairperson), KUSH M PARMAR, MANJA BOERMAN
Corporate Social Responsibility Committee CATHERINE PATRICIA ROSENBERG (Chairperson), VINITA BALI, SANJAYA SINGH, SHARMILA ABHAY KARVE
Science and Technology Committee MANJA BOERMAN (Chairperson), CATHERINE PATRICIA ROSENBERG, KUSH M PARMAR, SANJAYA SINGH

Group Structure of Syngene International Limited

Syngene International Limited has 2 subsidiary companies. This group structure data is as of FY 2024. The corporate group structure reflects Syngene International Limited's business expansion strategy and organizational complexity.

2
Subsidiary companies
Key Subsidiaries
Company Name CIN Shares Held
Syngene Manufacturing Solutions Limited U24290KA2022PLC165409 -
Syngene Scientific Solutions Limited U73200KA2022PLC164804 -

Showing major subsidiaries. Total: 2.

Charges & Borrowings of Syngene International Limited

Open charges
₹375 Cr
Satisfied charges
₹1,783.71 Cr
Breakdown by lending institutions
Others₹1,415.03 Cr
The Hongkong and Shanghai Banking Corporation Limited₹163.65 Cr
State Bank of India₹90.00 Cr
Abn Amro Bank N. V.₹50.00 Cr
The Bank of Nova Scotia₹50.00 Cr
Others₹15.04 Cr
Latest charge details
DateLenderAmountStatus
03 Aug 2021 Others ₹370.03 Cr Satisfied
30 Mar 2021 Others ₹375 Cr Satisfied
15 Sep 2016 Others ₹670 Cr Satisfied
28 Feb 2011 The Bank of Nova Scotia ₹50 Cr Satisfied
27 Sep 2008 State Bank of India ₹10 Cr Satisfied

Total charge records: 10 View all charges

Employees and EPFO Compliance at Syngene International Limited

Syngene International Limited has a workforce of 5,599 employees as of Oct 10, 2025.

Employee count
5,599
Active EPFO establishments
1
Employee growth
-3.88%
Premium access

Employee and EPFO history for Syngene International Limited

Monthly headcount, contribution history, establishment records, and filing compliance require an active report plan.

  • Monthly headcount
  • PF contributions
  • ECR filing status
  • Establishment history

Verified entity values are shown only after access is granted.

GST Compliance of Syngene International Limited

Premium access

GST registrations and filing compliance for Syngene International Limited

State-wise registrations, return filing status, HSN and SAC details, and jurisdiction records require an active report plan.

  • GSTIN registrations
  • State-wise filing status
  • HSN and SAC details
  • Tax jurisdiction records

Verified entity values are shown only after access is granted.

Credit Ratings, Litigation & Regulatory Alerts for Syngene International Limited

Premium access

Credit ratings, litigation, and regulatory alerts for Syngene International Limited

Agency ratings, court records, regulatory events, and entity-specific compliance alerts require an active report plan.

  • Rating history
  • Court and tribunal cases
  • Regulatory alerts
  • Director-linked violations

Verified entity values are shown only after access is granted.

MSME Payment Delays by Syngene International Limited

Premium access

MSME payment history for Syngene International Limited

Amounts outstanding to micro and small suppliers, delay reasons, and MSME-1 filing history require an active report plan.

  • Outstanding amounts
  • Delay periods and reasons
  • MSME-1 filing history
  • Vendor payment signals

Verified entity values are shown only after access is granted.

Subsidiaries & Group Companies of Syngene International Limited

Premium access

Corporate group structure for Syngene International Limited

Parent, subsidiary, associate, joint venture, and ownership records require an active report plan.

  • Parent company
  • Subsidiaries and ownership
  • Associates and joint ventures
  • Entity investments

Verified entity values are shown only after access is granted.

MCA Filings & Documents of Syngene International Limited

Premium access

MCA filings and documents for Syngene International Limited

Official forms, annual returns, financial statements, charge filings, and document dates require an active report plan.

  • Incorporation documents
  • Annual returns and statements
  • Charge filings
  • Complete filing index

Verified entity values are shown only after access is granted.

Recent Activity on Syngene International Limited

Directors
14 Jul 2026
Siddharth Mittal was appointed as a Ceo on 14 Jul 2026 & has been associated with this company since 7 days.
Directors
01 Jul 2026
Siddharth Mittal was appointed as a Additional Director on 01 Jul 2026 & has been associated with this company since 20 days.
Charges
23 Apr 2026
A charge registered on 30 Mar 2021 via Charge ID 100439676 with Others was fully satisfied on 23 Apr 2026.
Charges
29 Oct 2025
A charge with Others of Rs. 375.00 Cr registered on 30 Mar 2021 with Charge ID 100439676 was modified on 29 Oct 2025.
Directors
05 Aug 2025
Chethan Yogesh was appointed as a Company Secretary on 05 Aug 2025 & has been associated with this company since 11 months 16 days.
Directors
01 Aug 2025
Suresh Narayanan was appointed as a Director on 01 Aug 2025 & has been associated with this company since 11 months 20 days.

Recent News on Syngene International Limited

Stocks that will see action today: March 11, 2025
11 Mar 2025 · Thehindubusinessline
Stocks that will see action today: January 23, 2025
23 Jan 2025 · Thehindubusinessline

Frequently Asked Questions about Syngene International Limited

Syngene International Limited is an active public limited company in the pharma sector based in Bangalore, Karnataka, India. It was incorporated on 18 November 1993 (33+ years old) and is registered under CIN L85110KA1993PLC014937. Listed on BSE: 539268 and NSE: SYNGENE. The company has 5,599 employees.

Syngene International Limited reported revenue of ₹3,738.7 Cr for FY 2026 (up 2.64% YoY) based on consolidated NSE filings.

The current directors of Syngene International Limited are:

The primary industry of Syngene International Limited is pharma. The company specifically operates in pharma contract r and d. The company is currently active in this sector.

Yes. Syngene International Limited is listed on both BSE (code: 539268) and NSE (symbol: SYNGENE).

Syngene International Limited can be reached at the registered office: Biocon Sez Biocon Park Plot.No.2 & 3 Bommasandra Indst. Area Iv Phase Jigani Link Rd Bo, Mmasandra, Bangalore, Karnataka, India – 560099, or through the website syngeneintl.com.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - sourced from MCA, SEBI and RBI filings.

Subscription plans available